Global Methamphetamine Use: Overview and Epidemiological Profile
Methamphetamine use is rising sharply in South-East Asia, causing psychosis, dependence and other harms. This report covers methamphetamine pills and crystal methamphetamine.
Burden: Prevalence, Incidence and Mortality
The report sets out the prevalence, incidence and, where relevant, deaths from methamphetamine use worldwide, and the overall burden, using Prevalence, Treatment Gap, Suicide Rate, Service Coverage and Mental Health Workforce.
Demographic Distribution: Age, Gender and Vulnerable Population Groups
The burden is broken down by age (children 5–14 years, adolescents 15–19 years, young adults 20–29 years, adults 30–59 years and adults 60 years and over), gender and income, with a focus on adolescents and young people, women in pregnancy and after birth, people affected by conflict, refugees and migrants, people who use drugs and people with chronic illness.
Geographical Distribution: State, District, Urban and Rural Segmentation
Findings are compared across states, provinces and districts where data allows, and between urban, rural and informal settlement areas, to show where needs are greatest and where gaps between places are widest.
Risk Factors and Social Determinants of Health
Main risk factors include poverty and unemployment, violence and trauma, conflict and displacement, substance use, social isolation and stigma. Income, education, housing, water and sanitation, and gender and social norms are reviewed as social drivers of health.
Awareness and Screening Coverage
The report reviews how aware people are of methamphetamine use and how far screening reaches them, through screening in primary care, school and community screening, validated screening tools and helplines, by group and by area.
Diagnosis Rates and Undiagnosed Burden
It compares the number of people diagnosed with the estimated number affected, to show the undiagnosed burden and how many people are lost between screening and treatment.
Treatment, Prevention and Coverage
Treatment and prevention covered include psychosocial treatment, community-based treatment, harm reduction and prevention in young people, with how many people receive treatment and how many stay on it.
Health Outcomes and Complications
Long-term effects covered include disability, suicide and self-harm, lost education and work and physical health problems, along with other conditions that often occur alongside methamphetamine use.
Healthcare Infrastructure and Accessibility
The report looks at primary care, community mental health services, psychiatric units in general hospitals and mental health workforce, the health workforce, and the physical, financial and distance barriers to care, including how people use public and private services.
Economic and Socioeconomic Burden
Methamphetamine Use worldwide: health cover, spending and research
WHO reports that 4.5 billion people were not fully covered by essential health services in 2021.[1] The world scores 71 out of 100 on the WHO universal health coverage index (2023).[2] People pay 17.3% of all health spending out of their own pockets (2023).[3] ClinicalTrials.gov lists 45 studies on Methamphetamine Use that are recruiting, active or about to start worldwide.[4]
It describes the costs of methamphetamine use to health systems and households, including out-of-pocket spending and lost productivity, and how government, donors and NGOs fund the response.
Government Initiatives and Public Health Interventions
Worldwide guidance and funding for methamphetamine use include WHO Comprehensive Mental Health Action Plan 2013–2030, WHO Mental Health Gap Action Programme (mhGAP), WHO Special Initiative for Mental Health and IASC Guidelines on Mental Health and Psychosocial Support in Emergencies. The report reviews national programmes, donor and NGO funding, and what is known about their impact.
Historical Trends and Comparative Analysis
Year-wise trends and changes across survey rounds are shown and compared with peer countries, with the data collection year and reporting period stated for each figure.
Healthcare Gaps and Unmet Needs
The report names gaps in screening, diagnosis, treatment and access, the high-risk and underserved communities most affected, and where reliable data is missing.
Future Burden and Public Health Outlook
It looks ahead at the likely future burden of methamphetamine use, the healthcare it will need and the areas most vulnerable.
Key Findings and Strategic Recommendations
The report closes with key findings, the population groups to prioritise and recommendations on where to target resources. Figures come from WHO Mental Health Atlas, Global Burden of Disease (IHME), National Mental Health Surveys and UNODC World Drug Report. Reported cases, survey estimates and modelled estimates are kept apart, and missing figures are named as data gaps.
The methamphetamine use burden in this report is segmented by type, age group, gender, population group, area, socioeconomic status and care setting. Here's a breakdown of the segmentation
By Type
- Methamphetamine Pills
- Crystal Methamphetamine
By Age Group
- Children 5–14 Years
- Adolescents 15–19 Years
- Young Adults 20–29 Years
- Adults 30–59 Years
- Adults 60 Years and Over
By Population Group
- Adolescents and Young People
- Women in Pregnancy and After Birth
- People Affected by Conflict
- Refugees and Migrants
- People Who Use Drugs
- People With Chronic Illness
By Area
- Urban
- Rural
- Informal Settlements and Camps
By Socioeconomic Status
- Poorest Households
- Lower-Middle
- Middle
- Upper-Middle
- Richest Households
By Care Setting
- Public Health Facilities
- Private Facilities and Pharmacies
- NGO and Faith-Based Facilities
- Community-Based Care